WEDNESDAY, July 31, 2019 (HealthDay News) — A U.S. clinical trial of CRISPR gene-editing to treat people with sickle cell disease is underway.
The trial will use CRISPR in an attempt to boost production of a different kind of hemoglobin (fetal hemoglobin) that makes it harder for cells to sickle and stick together, CNN reported.
Sickle cell disease affects about 100,000 Americans, most of African ancestry or identifying as black.
Copyright © 2019 HealthDay. All rights reserved.